Médecine

Paramédical

Autres domaines


S'abonner

Treatment of acquired bilateral nevus of Ota-like macules (Hori's nevus) using a combination of scanned carbon dioxide laser followed by Q-switched ruby laser - 29/08/11

Doi : 10.1067/mjd.2003.193 
Woraphong Manuskiatti, MDa, Apichati Sivayathorn, MDa, Panadda Leelaudomlipi, MDa, Richard E. Fitzpatrick, MDb
Bangkok, Thailand, and Encinitas, California 
From the Department of Dermatology, Siriraj Hospital, Mahidol University,a and Dermatology Associates/Cosmetic Laser Associates of San Diego County Inc.b 

Abstract

Background: Acquired bilateral nevus of Ota-like macules (Hori's nevus) is a dermal pigmented lesion commonly seen in middle-aged women of Asian descent. The Q-switched ruby laser (QSRL) has been used successfully to treat a variety of benign pigmented lesions. Multiple, sequential treatments are typically required for complete clearance of the dermal pigmented dermatoses. Objective: The purpose of this study was to determine the efficacy of QSRL in the treatment of Hori's nevus and the beneficial effect of epidermal ablation using the scanned carbon dioxide (CO2) laser before QSRL. Methods: A total of 13 women from Thailand with Hori's nevus were randomly treated with the scanned CO2 laser followed by QSRL on one side of their face, and QSRL alone on the other side. The same fluence of QSRL was used on both sides in individual patients. The treatment response was objectively evaluated by measuring the melanin index using a Mexameter (Courage & Khazaka Electronic GmbH, Köln, Germany), and subjectively assessed by the patients before treatment and 3 and 16 months after treatment. Adverse sequelae of the treatment and the patients' tolerance were also evaluated at the same follow-up visit. Results: The 3- and 16-month posttreatment melanin index was significantly decreased compared with that of pretreatment on both treated sites and this corresponded to the patients' subjective evaluations. The response rate, defined as “the percentage of reduction in melanin index,” was significantly higher on the sides treated with scanned CO2 laser followed by QSRL, compared with the sides irradiated with QSRL alone at both follow-up visits. At the 3-month follow-up, the most common adverse effect was hypopigmentation, found in 15% (2 of 13) of the patients on the sites treated with QSRL alone, and on the sites treated with scanned CO2 laser followed by QSRL (8%, 1/13). Erythema was observed in 15% (2/13) of the patients only on the sites that received combination treatment. However, no adverse sequelae were observed at the 16-month posttreatment follow-up. Conclusion: Epidermal ablation with scanned CO2 laser before the use of the pigment-specific laser may be an effective technique for increasing therapeutic efficacy in the treatment of dermal pigmented dermatoses. (J Am Acad Dermatol 2003;48:584-91.)

Le texte complet de cet article est disponible en PDF.

Plan


 Funding sources: None.
 Conflict of interest: None identified.
 Reprint requests: Woraphong Manuskiatti, MD, Department of Dermatology, Siriraj Hospital, 2 Pran-nok Rd, Bangkok 10700, Thailand. E-mail: siwmn@mahidol.ac.th.
 0190-9622/2003/$30.00 + 0


© 2003  American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 48 - N° 4

P. 584-591 - avril 2003 Retour au numéro
Article précédent Article précédent
  • Mizolastine in primary acquired cold urticaria
  • Louis Dubertret, Catherine Pecquet, Margarita Murrieta-Aguttes, Francisque Leynadier
| Article suivant Article suivant
  • The economic burden of skin disease in the United States
  • Seena Dehkharghani, Jason Bible, John G. Chen, Steven R. Feldman, Alan B. Fleischer

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.